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Large-scale clinical trials have been the cornerstone of evidence-based medicine 
in cardiology for nearly 40 years.  The results of these trials have led to justified 
confidence in most of our current treatments and have also identified 
interventions that have been ineffective or harmful.  When planned and executed 
meticulously and analyzed to minimize bias, large-scale trials have provided 
strong foundational support for the use of both drugs and devices for millions of 
people.  However, recent changes in the practice of medicine and the business 
of clinical trials have threatened many of the operational principles that have 
successfully guided the conduct of these important studies.   These changes may 
lead us to rethink our ability to rely on them for decision-making in cardiology, 
and particularly, with respect to the management of heart failure. 
 
Risk-Reward Relationship for Conducting Large-Scale Trials Has Shifted 
 
Demonstration of the efficacy and safety of cardiovascular interventions has 
generally required the enrollment of thousands of at-risk patients who are 
randomly assigned to one of several treatment arms and followed compulsively 
for long periods of time.  This approach generates the large number of clinically 
relevant events required to demonstrate the modest treatment effect sizes 
typically seen in largely undifferentiated groups of patients with cardiovascular 
disease, including those with acute or chronic heart failure. 
 
This traditional approach to trials in cardiology differs strikingly from the principles 
govern the conduct of trials in oncology.1,2  Currently, most oncology trials 
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evaluate treatments that are designed to disrupt a highly specific molecular target, 
whose presence in individual patients can be identified prior to enrollment.  
Therefore, although the eventual number of patients who might be treated in 
clinical practice may be small (< 10,000-100,000 patients), the expected 
magnitude of the treatment effect is often large (60-80% reduction in risk).  
Furthermore, oncology trials often are designed around biomarkers as their 
primary endpoints, typically those that reflect the abnormal proliferation of 
malignant cells.  As a result, oncology trials frequently focus on “disease or 
biomarker progression” rather than mortality, and because biomarker progression 
is a common occurrence and the effect sizes are often dramatic, the trials are 
typically small (<500 patients).  The trials recruit rapidly because patients with the 
genetically-defined cancer are already under the care of specialists who serve as 
investigators.  If the disease has a highly predictable adverse outcome, a 
dramatic result can be persuasive, even in a small trial that is carried out on a 
surrogate endpoint, and often in the absence of a control group. 
 
These features stand in marked contrast with the conditions that prevail when 
novel drugs are developed for patients with cardiovascular disease.  An 
understanding of the genetics of cardiac disorders remains in its infancy, and 
specific molecular targets have not been identified as a valid basis for identifying 
subgroups with predictable responses to distinctive treatments.  Interventions in 
cardiology typically focus on one of many pathophysiological (rather than 
genetic) mechanisms that contribute to but do not necessarily play a crucial role 
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in a disease process.  Interference with only one of many contributory 
mechanisms can be expected to have only a modest benefit (10-25% risk 
reduction), and there are few reliable surrogate endpoints.  Hence, trials must 
track the occurrence of large numbers of fatal and non-fatal events of 
unquestioned clinical relevance.  The most commonly measured nonfatal 
outcome in heart failure trials is hospitalization for worsening heart failure, but 
this endpoint depends on physician judgment, institutional policy and available 
healthcare resources.  As event rates have declined over several decades, the 
size of large-scale outcome trials has necessarily soared, despite their increasing 
reliance on composite endpoints.  The typical large-scale cardiovascular 
outcomes trial seeks to enroll 5000-20,000 patients and often takes 7-10 years to 
complete.   
 
If a trial succeeds on its primary endpoint and the novel intervention is approved 
for clinical use, companies that develop drugs for cancer can price them at 
exorbitant levels (often exceeding $300,000 per year).3  Although the number of 
patients who are eligible for treatment is small, the new drug is rapidly adopted 
by cancer specialists, and the resulting revenues rapidly exceed the costs of 
performing the small pivotal clinical trial that demonstrated efficacy.  In contrast, 
a new cardiovascular drug — because of its modest effect size and potential use 
by millions of people — typically faces significant price constraints and onerous 
preauthorization requirements, even if the treatment costs only a small fraction of 
that of a new oncology drug. Furthermore, most patients with common 
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cardiovascular disorders (such as heart failure) are cared for by primary care 
physicians, who generally have not instituted the administrative procedures 
needed to tackle preauthorization requirements.  Therefore, the adoption of a 
new cardiovascular drug by generalists is slow; a sponsor can expect the 
revenues of a newly-approved cardiovascular drug to recoup the costs of large-
scale trial only after many years, if ever. 
 
As a result of the interplay of these socioeconomic forces, the development of 
novel cardiovascular drugs has slowed markedly in recent years, and in parallel, 
the number of large-scale cardiovascular outcome trials has dwindled.1  Given 
the high likelihood of failure and (when successful) the long lead-time to recoup 
the costs of a substantial financial investment (often > $300 million), the risk-
reward relationship for carrying out these trials is no longer favorable. 
 
Investigator Base for Large-Scale Trials Has Been Transformed 
 
Twenty to 30 years ago, it was common for large-scale cardiovascular outcome 
trials to be carried out by highly motivated clinical investigators, who largely 
worked at academic medical centers and were allowed (and even encouraged) to 
devote a portion of their professional time and energy to participation in clinical 
research.   North American and Western European centers played a major role in 
trials, and the infrastructure to support the recruitment of patients (e.g., 
experienced study coordinators) was well-established.  However, in recent years, 
healthcare systems have placed enormous pressures on physicians to generate 
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clinical revenues, and thus, the time available for clinical research activities has 
evaporated.  In any fixed time frame, the revenues that a clinical investigator can 
generate from clinical trials are no longer competitive with the revenues that they 
can generate by seeing large numbers of patients at a rapid pace or by 
performing interventional or imaging procedures.  Furthermore, many physicians 
no longer feel an obligation to contribute to medical progress or may fear 
surrendering control of their patients.  At the same time, some patients may 
harbor suspicions that their participation in a long-term trial is likely to provide 
greater financial rewards to the clinical investigator than direct health benefits to 
themselves. 
 
As a result, recruitment efforts in large-scale clinical trials have shifted to Eastern 
Europe, Asia and Latin America, where enthusiastic investigators can still be 
found and where the patient-physician relationship is likely to be more trustful.  In 
some geographical regions, participation in a clinical trial may provide the only 
opportunity for patients to obtain good medical care.  The cost of establishing an 
investigative site in these geographical regions is comparative low, and the 
revenues generated from clinical research often provide a critical supplement to 
the relatively meager salaries of investigators.  In North America and Western 
Europe, private practices have superseded academic medical centers as 
investigative sites, because they are able to structure the recruitment and care of 
patients far more efficiently than their counterparts at medical schools.  
Regardless of geography, many (perhaps most) investigative sites now view 
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clinical trials primarily as a business opportunity, rather than a research 
enterprise.  This shift in thinking means that investigators are primarily motivated 
to maximize trial revenues rather than to answer a specific research question. 
 
This shift in the investigator base has affected trials regardless of the sponsoring 
organization.  Even trials sponsored by the National Heart, Lung and Blood 
Institute (NHLBI) have moved to unfamiliar geographical regions or investigative 
sites.  Because these sites are often lightly supervised, recent NHLBI-sponsored 
cardiovascular trials (such as TOPCAT and SPRINT) have been characterized 
by a significant heterogeneity in the types of patients who have been enrolled or 
in the ways that study procedures have been carried out.  This heterogeneity has 
led to a meaningful degree of uncertainty about the results of these trials, leading 
to controversy about their implications for clinical practice.4,5 
 
Contract Research Organizations Supervise the Quality of Work 
 
The ability of trials to effectively answer a research question depends 
substantially on the quality of work carried out at investigative sites, and in the 
past, assurances about quality was possible because the work could be closely 
monitored by auditors who were able to confirm the validity of recorded data.  
Although  research carried out by the NHLBI was not typically closely monitored, 
trials conducted by large pharmaceutical companies were meticulously 
supervised, often by teams of full-time highly trained professionals with a primary 
allegiance to the integrity of the trial. 
This article is protected by copyright. All rights reserved.
 
However, during the past 20-30 years, these experienced in-house monitoring 
teams have largely disappeared.  Large pharmaceutical companies have 
eliminated much of this internal infrastructure in their efforts to streamline costs.  
Small start-up companies never had the opportunity or resources to establish 
these internal quality-assurance teams in the first place.  As a result, drug 
sponsors — regardless of size — now rely heavily on contract research 
organizations to identify and supervise investigative sites.   
 
Not surprisingly, these contract research organizations (CRO) emerged as a 
business enterprise in their own right.  They were designed not only to deliver a 
product, but also to make a profit.  Capitalizing on the price sensitivity of 
pharmaceutical sponsors (large or small), it was tempting for CROs to submit a 
low bid for services but then to deliver even lower-quality monitoring.  Recently, 
to further reduce expenses, some CROs have shifted to “risk-based monitoring”, 
a strategy where only sites with the highest possibility of mischief would be 
closely monitored.  However, it has been difficult to validate the worthiness of the 
algorithms used to identify risk, and these algorithms are not necessarily updated 
if the study personnel at a previously reliable site change.  The inevitable result 
of cost-cutting is that certain operational deficiencies are unlikely to be detected.  
To complicate matters further, since CROs are under significant financial 
pressure to meet recruitment targets, they may have little motivation to pursue 
potentially suspicious investigative activities and are understandably reluctant to 
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take punitive actions at a questionable site that is recruiting well.  In truth, the 
likelihood that the sponsor would ever become aware of or be able to prove a 
lapse in study quality was remote.  
 
With the outsourcing of many (and often most) elements of the clinical trial 
operations and execution, pharmaceutical sponsors effectively delegated large 
components of a trial’s conduct to business entities that had no vested interest in 
the study outcome.  For many companies, there was no viable alternative.  
Privately, sponsors prayed that their novel drug would be so effective that the 
trial would be able to detect a meaningful treatment effect, even if issues related 
to study quality created a substantial amount of background noise.  Additionally, 
since lapses in study quality typically generate data that bias a result to the null, 
sponsors often compensated by making their trials even larger — and thus, more 
susceptible to the vagaries of recruitment and quality control. 
 
Shift Toward Large-Scale Pragmatic Trials Carries Major Risks 
 
Given these uncertainties, corporate and government sponsors have been 
reluctant to make the enormous investment that has traditionally been required to 
conduct large-scale cardiovascular outcomes trials.  Understandably, they have 
become keenly interested in any proposals that might allow the execution of 
these enormous trials at a fraction of their current cost.  Suppose a trial could be 
carried out with minimal involvement by investigators and with minimal 
supervision.  Theoretically, potential patients could respond to an online 
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announcement; a website could provide all informational elements and informed 
consent and allow self-recruitment.  Patients could be sent their assigned 
medication by mail or could collect it at central distribution facilities.  Visits could 
be conducted electronically; adherence with the assigned medication (and the 
reporting of adverse effects) could be documented by self-report; and information 
about endpoint events could be obtained through electronic medical records or 
public databases.  Such measures, taken collectively, constitute the primary 
elements of what is currently referred to as a “pragmatic” randomized trial. 
 
Technically, the “pragmatic” trial has been distinguished from the “explanatory” 
trial.6-8  The traditional “explanatory” trial seeks to control all potentially 
confounding factors in order to discern evidence for a treatment effect.  In 
contrast, although treatment assignments are still randomized, the “pragmatic” 
trial seeks to control as few operational issues as possible, thus allowing the 
recruitment of large numbers of patients with minimal infrastructure and cost.  
Although some might believe that a pragmatic trial determines whether a drug 
works in “real life”, the distinction between an “explanatory” and “pragmatic” trial 
lies not in its clinical applicability, but in its operational features.  The pragmatic 
trial places most of the responsibility of study conduct on the trial participants, 
virtually eliminating the need for investigators, research coordinators or 
supervisory structure.  In its most basic form, a trial can be carried out entirely 
based on the interaction between a study participant and a website. 
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What kind of information can we expect when these pragmatic trials are applied 
to questions in cardiovascular medicine?   We can reasonably anticipate — if 
appropriately publicized — that recruitment will be rapid; potentially, tens of 
thousands of people could be randomized in months, rather than years.  
Furthermore, the costs of the trial could be reduced dramatically, perhaps down 
to 5% of the cost of a conventionally-executed phase III trial.  Yet, every other 
aspect of the conduct of a pragmatic trial would increase uncertainty.  Left 
unsupervised, participants might or might not be adherent with their study 
medication, compliant with the forms required at each study visit or responsive to 
phone calls or other electronic means of follow-up.  Unless actively motivated, 
people might be less likely to maintain participation for long periods of time, and 
the ascertainment of study endpoints is likely to be less complete.  The 
predictable consequence of a pragmatic trial would be an increase in background 
noise, thus driving the estimated effect size towards the null, assuming that the 
trial were analyzed according to the intention-to-treat principle.  Of course, a 
treatment effect might still be detected and reach conventional levels of statistical 
significance if the trial recruited an exceptionally large number of patients. 
 
Are these pragmatic trials the wave of the future?  The question is not whether 
these trials will be less costly, but whether such trials will be capable of 
generating persuasive evidence that can change clinical practice.  Suppose a 
trial were to enroll 50,000 patients, who were randomized 1:1 to one of two 
treatment arms.  Suppose that 20% of patients did not take the study medication; 
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another 20% did not comply with study procedures; and another 20% did not 
provide data on endpoints.  In the end, by intention-to-treat analysis, one group 
of patients might have a lower risk of a major adverse clinical outcome (P< 
0.001).  Yet, because of the numerous factors that nudge the effect size towards 
the null, the magnitude of the actually observed treatment effect may be quite 
small, even for an intervention that truly has a meaningful therapeutic benefit.  A 
drug that would be shown to reduce mortality by 20-25% in a conventionally 
executed trial might produce only a 3-10% reduction in relative risk in a large-
scale pragmatic trial.  At its completion, the trial might achieve preplanned levels 
of statistical significance, but will anyone care?  At worst, the factors that bias the 
result to the null might entirely obliterate the ability of the study to detect a true 
treatment difference.  Certainly, if the pragmatic trial yields a false negative result 
or reports an effect size that appears tiny and unpersuasive by conventional 
standards, then even the paltry sums invested in it will have been wasted.  The 
widely-held belief that a pragmatic trial provides “real-world” evidence is 
seductively appealing, but no one has shown that such trials are more likely to 
yield the truth.  They are certainly more likely to yield results that do not matter. 
 
For these cogent reasons, pragmatic trials are unlikely to be utilized by the drug 
or device industry for the registration of novel interventions.  However, pragmatic 
trial designs might have a role in answering important questions about already-
approved medications, e.g., particularly in addressing uncertainties related to 
dose of an established drug or the comparative effectiveness of two treatments.  
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The NHLBI is currently carrying out two large-scale pragmatic trials in patients 
with chronic heart failure.  The TRANSFORM trial9 will enroll 6000 recently-
hospitalized patients who will be randomized (open-label) to furosemide or 
torsemide, with total mortality as the primary endpoint.  The SPIRRIT trial10 
(carried out in partnership with the Swedish Heart Foundation and the Swedish 
Ministry of Health and Social Affairs) will enroll 3200 patients with chronic heart 
failure and an ejection fraction > 40%, who will be randomized (open-label) to 
receive spironolactone or no spironolactone and be followed for the occurrence 
of cardiovascular death or hospitalization for heart failure.  Ascertainment of 
study endpoints will be accomplished through national death index or healthcare 
registry.  Neither trial will rely on physical visits by participants to a clinical 
research site.  Conceivably, further technological advances (e.g. geofencing) 
may allow trialists to reliably obtain information on patient outcomes without any 




If research in cardiovascular disease fails to identify critical causal abnormalities 
in highly select populations and if drug development continues to focus on the 
modulation of mechanisms that play only a small contributory role, then 
traditional large-scale clinical trials involving thousands of patients will be needed 
to demonstrate worthwhile treatment effects.  Because of the need to minimize 
operational factors that create statistical noise, these trials will continue to be 
extraordinarily expensive, and current trends in society and in medicine will 
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continue to present important operational challenges.  If a traditionally-executed 
trial demonstrates a modest therapeutic effect but the price of the novel agent 
carries an innovative premium, the new drug may not be rapidly adopted, and the 
revenues that were used to justify the trial’s expense may not materialize in a 
timely manner.  Pragmatic trials are seductively less expensive, but may yield 
results that generate little enthusiasm or be difficult to interpret.  Therefore, 
unless the science underlying cardiovascular drug development changes 
dramatically, we may not need to worry about how large-scale clinical trials in 
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Large-scale clinical trials have been the cornerstone of evidence-based medicine 
in cardiology for nearly 40 years.  The results of these trials have led to justified 
confidence in most of our current treatments and have also identified 
interventions that have been ineffective or harmful.  When planned and executed 
meticulously and analyzed to minimize bias, large-scale trials have provided 
strong foundational support for the use of both drugs and devices for millions of 
people.  However, recent changes in the practice of medicine and the business 
of clinical trials have threatened many of the operational principles that have 
successfully guided the conduct of these important studies.   These changes may 
lead us to rethink our ability to rely on them for decision-making in cardiology, 
and particularly, with respect to the management of heart failure. 
 
Risk-Reward Relationship for Conducting Large-Scale Trials Has Shifted 
 
Demonstration of the efficacy and safety of cardiovascular interventions has 
generally required the enrollment of thousands of at-risk patients who are 
randomly assigned to one of several treatment arms and followed compulsively 
for long periods of time.  This approach generates the large number of clinically 
relevant events required to demonstrate the modest treatment effect sizes 
typically seen in largely undifferentiated groups of patients with cardiovascular 
disease, including those with acute or chronic heart failure. 
 
This traditional approach to trials in cardiology differs strikingly from the principles 
govern the conduct of trials in oncology.1,2  Currently, most oncology trials 
evaluate treatments that are designed to disrupt a highly specific molecular target, 
whose presence in individual patients can be identified prior to enrollment.  
Therefore, although the eventual number of patients who might be treated in 
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clinical practice may be small (< 10,000-100,000 patients), the expected 
magnitude of the treatment effect is often large (60-80% reduction in risk).  
Furthermore, oncology trials often are designed around biomarkers as their 
primary endpoints, typically those that reflect the abnormal proliferation of 
malignant cells.  As a result, oncology trials frequently focus on “disease or 
biomarker progression” rather than mortality, and because biomarker progression 
is a common occurrence and the effect sizes are often dramatic, the trials are 
typically small (<500 patients).  The trials recruit rapidly because patients with the 
genetically-defined cancer are already under the care of specialists who serve as 
investigators.  If the disease has a highly predictable adverse outcome, a 
dramatic result can be persuasive, even in a small trial that is carried out on a 
surrogate endpoint, and often in the absence of a control group. 
 
These features stand in marked contrast with the conditions that prevail when 
novel drugs are developed for patients with cardiovascular disease.  An 
understanding of the genetics of cardiac disorders remains in its infancy, and 
specific molecular targets have not been identified as a valid basis for identifying 
subgroups with predictable responses to distinctive treatments.  Interventions in 
cardiology typically focus on one of many pathophysiological (rather than 
genetic) mechanisms that contribute to but do not necessarily play a crucial role 
in a disease process.  Interference with only one of many contributory 
mechanisms can be expected to have only a modest benefit (10-25% risk 
reduction), and there are few reliable surrogate endpoints.  Hence, trials must 
track the occurrence of large numbers of fatal and non-fatal events of 
unquestioned clinical relevance.  The most commonly measured nonfatal 
outcome in heart failure trials is hospitalization for worsening heart failure, but 
this endpoint depends on physician judgment, institutional policy and available 
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healthcare resources.  As event rates have declined over several decades, the 
size of large-scale outcome trials has necessarily soared, despite their increasing 
reliance on composite endpoints.  The typical large-scale cardiovascular 
outcomes trial seeks to enroll 5000-20,000 patients and often takes 7-10 years to 
complete.   
 
If a trial succeeds on its primary endpoint and the novel intervention is approved 
for clinical use, companies that develop drugs for cancer can price them at 
exorbitant levels (often exceeding $300,000 per year).3  Although the number of 
patients who are eligible for treatment is small, the new drug is rapidly adopted 
by cancer specialists, and the resulting revenues rapidly exceed the costs of 
performing the small pivotal clinical trial that demonstrated efficacy.  In contrast, 
a new cardiovascular drug — because of its modest effect size and potential use 
by millions of people — typically faces significant price constraints and onerous 
preauthorization requirements, even if the treatment costs only a small fraction of 
that of a new oncology drug. Furthermore, most patients with common 
cardiovascular disorders (such as heart failure) are cared for by primary care 
physicians, who generally have not instituted the administrative procedures 
needed to tackle preauthorization requirements.  Therefore, the adoption of a 
new cardiovascular drug by generalists is slow; a sponsor can expect the 
revenues of a newly-approved cardiovascular drug to recoup the costs of large-
scale trial only after many years, if ever. 
 
As a result of the interplay of these socioeconomic forces, the development of 
novel cardiovascular drugs has slowed markedly in recent years, and in parallel, 
the number of large-scale cardiovascular outcome trials has dwindled.1  Given 
the high likelihood of failure and (when successful) the long lead-time to recoup 
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the costs of a substantial financial investment (often > $300 million), the risk-
reward relationship for carrying out these trials is no longer favorable. 
 
Investigator Base for Large-Scale Trials Has Been Transformed 
 
Twenty to 30 years ago, it was common for large-scale cardiovascular outcome 
trials to be carried out by highly motivated clinical investigators, who largely 
worked at academic medical centers and were allowed (and even encouraged) to 
devote a portion of their professional time and energy to participation in clinical 
research.   North American and Western European centers played a major role in 
trials, and the infrastructure to support the recruitment of patients (e.g., 
experienced study coordinators) was well-established.  However, in recent years, 
healthcare systems have placed enormous pressures on physicians to generate 
clinical revenues, and thus, the time available for clinical research activities has 
evaporated.  In any fixed time frame, the revenues that a clinical investigator can 
generate from clinical trials are no longer competitive with the revenues that they 
can generate by seeing large numbers of patients at a rapid pace or by 
performing interventional or imaging procedures.  Furthermore, many physicians 
no longer feel an obligation to contribute to medical progress or may fear 
surrendering control of their patients.  At the same time, some patients may 
harbor suspicions that their participation in a long-term trial is likely to provide 
greater financial rewards to the clinical investigator than direct health benefits to 
themselves. 
 
As a result, recruitment efforts in large-scale clinical trials have shifted to Eastern 
Europe, Asia and Latin America, where enthusiastic investigators can still be 
found and where the patient-physician relationship is likely to be more trustful.  In 
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some geographical regions, participation in a clinical trial may provide the only 
opportunity for patients to obtain good medical care.  The cost of establishing an 
investigative site in these geographical regions is comparative low, and the 
revenues generated from clinical research often provide a critical supplement to 
the relatively meager salaries of investigators.  In North America and Western 
Europe, private practices have superseded academic medical centers as 
investigative sites, because they are able to structure the recruitment and care of 
patients far more efficiently than their counterparts at medical schools.  
Regardless of geography, many (perhaps most) investigative sites now view 
clinical trials primarily as a business opportunity, rather than a research 
enterprise.  This shift in thinking means that investigators are primarily motivated 
to maximize trial revenues rather than to answer a specific research question. 
 
This shift in the investigator base has affected trials regardless of the sponsoring 
organization.  Even trials sponsored by the National Heart, Lung and Blood 
Institute (NHLBI) have moved to unfamiliar geographical regions or investigative 
sites.  Because these sites are often lightly supervised, recent NHLBI-sponsored 
cardiovascular trials (such as TOPCAT and SPRINT) have been characterized 
by a significant heterogeneity in the types of patients who have been enrolled or 
in the ways that study procedures have been carried out.  This heterogeneity has 
led to a meaningful degree of uncertainty about the results of these trials, leading 
to controversy about their implications for clinical practice.4,5 
 
Contract Research Organizations Supervise the Quality of Work 
 
The ability of trials to effectively answer a research question depends 
substantially on the quality of work carried out at investigative sites, and in the 
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past, assurances about quality was possible because the work could be closely 
monitored by auditors who were able to confirm the validity of recorded data.  
Although  research carried out by the NHLBI was not typically closely monitored, 
trials conducted by large pharmaceutical companies were meticulously 
supervised, often by teams of full-time highly trained professionals with a primary 
allegiance to the integrity of the trial. 
 
However, during the past 20-30 years, these experienced in-house monitoring 
teams have largely disappeared.  Large pharmaceutical companies have 
eliminated much of this internal infrastructure in their efforts to streamline costs.  
Small start-up companies never had the opportunity or resources to establish 
these internal quality-assurance teams in the first place.  As a result, drug 
sponsors — regardless of size — now rely heavily on contract research 
organizations to identify and supervise investigative sites.   
 
Not surprisingly, these contract research organizations (CRO) emerged as a 
business enterprise in their own right.  They were designed not only to deliver a 
product, but also to make a profit.  Capitalizing on the price sensitivity of 
pharmaceutical sponsors (large or small), it was tempting for CROs to submit a 
low bid for services but then to deliver even lower-quality monitoring.  Recently, 
to further reduce expenses, some CROs have shifted to “risk-based monitoring”, 
a strategy where only sites with the highest possibility of mischief would be 
closely monitored.  However, it has been difficult to validate the worthiness of the 
algorithms used to identify risk, and these algorithms are not necessarily updated 
if the study personnel at a previously reliable site change.  The inevitable result 
of cost-cutting is that certain operational deficiencies are unlikely to be detected.  
To complicate matters further, since CROs are under significant financial 
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pressure to meet recruitment targets, they may have little motivation to pursue 
potentially suspicious investigative activities and are understandably reluctant to 
take punitive actions at a questionable site that is recruiting well.  In truth, the 
likelihood that the sponsor would ever become aware of or be able to prove a 
lapse in study quality was remote.  
 
With the outsourcing of many (and often most) elements of the clinical trial 
operations and execution, pharmaceutical sponsors effectively delegated large 
components of a trial’s conduct to business entities that had no vested interest in 
the study outcome.  For many companies, there was no viable alternative.  
Privately, sponsors prayed that their novel drug would be so effective that the 
trial would be able to detect a meaningful treatment effect, even if issues related 
to study quality created a substantial amount of background noise.  Additionally, 
since lapses in study quality typically generate data that bias a result to the null, 
sponsors often compensated by making their trials even larger — and thus, more 
susceptible to the vagaries of recruitment and quality control. 
 
Shift Toward Large-Scale Pragmatic Trials Carries Major Risks 
 
Given these uncertainties, corporate and government sponsors have been 
reluctant to make the enormous investment that has traditionally been required to 
conduct large-scale cardiovascular outcomes trials.  Understandably, they have 
become keenly interested in any proposals that might allow the execution of 
these enormous trials at a fraction of their current cost.  Suppose a trial could be 
carried out with minimal involvement by investigators and with minimal 
supervision.  Theoretically, potential patients could respond to an online 
announcement; a website could provide all informational elements and informed 
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consent and allow self-recruitment.  Patients could be sent their assigned 
medication by mail or could collect it at central distribution facilities.  Visits could 
be conducted electronically; adherence with the assigned medication (and the 
reporting of adverse effects) could be documented by self-report; and information 
about endpoint events could be obtained through electronic medical records or 
public databases.  Such measures, taken collectively, constitute the primary 
elements of what is currently referred to as a “pragmatic” randomized trial. 
 
Technically, the “pragmatic” trial has been distinguished from the “explanatory” 
trial.6-8  The traditional “explanatory” trial seeks to control all potentially 
confounding factors in order to discern evidence for a treatment effect.  In 
contrast, although treatment assignments are still randomized, the “pragmatic” 
trial seeks to control as few operational issues as possible, thus allowing the 
recruitment of large numbers of patients with minimal infrastructure and cost.  
Although some might believe that a pragmatic trial determines whether a drug 
works in “real life”, the distinction between an “explanatory” and “pragmatic” trial 
lies not in its clinical applicability, but in its operational features.  The pragmatic 
trial places most of the responsibility of study conduct on the trial participants, 
virtually eliminating the need for investigators, research coordinators or 
supervisory structure.  In its most basic form, a trial can be carried out entirely 
based on the interaction between a study participant and a website. 
 
What kind of information can we expect when these pragmatic trials are applied 
to questions in cardiovascular medicine?   We can reasonably anticipate — if 
appropriately publicized — that recruitment will be rapid; potentially, tens of 
thousands of people could be randomized in months, rather than years.  
Furthermore, the costs of the trial could be reduced dramatically, perhaps down 
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to 5% of the cost of a conventionally-executed phase III trial.  Yet, every other 
aspect of the conduct of a pragmatic trial would increase uncertainty.  Left 
unsupervised, participants might or might not be adherent with their study 
medication, compliant with the forms required at each study visit or responsive to 
phone calls or other electronic means of follow-up.  Unless actively motivated, 
people might be less likely to maintain participation for long periods of time, and 
the ascertainment of study endpoints is likely to be less complete.  The 
predictable consequence of a pragmatic trial would be an increase in background 
noise, thus driving the estimated effect size towards the null, assuming that the 
trial were analyzed according to the intention-to-treat principle.  Of course, a 
treatment effect might still be detected and reach conventional levels of statistical 
significance if the trial recruited an exceptionally large number of patients. 
 
Are these pragmatic trials the wave of the future?  The question is not whether 
these trials will be less costly, but whether such trials will be capable of 
generating persuasive evidence that can change clinical practice.  Suppose a 
trial were to enroll 50,000 patients, who were randomized 1:1 to one of two 
treatment arms.  Suppose that 20% of patients did not take the study medication; 
another 20% did not comply with study procedures; and another 20% did not 
provide data on endpoints.  In the end, by intention-to-treat analysis, one group 
of patients might have a lower risk of a major adverse clinical outcome (P< 
0.001).  Yet, because of the numerous factors that nudge the effect size towards 
the null, the magnitude of the actually observed treatment effect may be quite 
small, even for an intervention that truly has a meaningful therapeutic benefit.  A 
drug that would be shown to reduce mortality by 20-25% in a conventionally 
executed trial might produce only a 3-10% reduction in relative risk in a large-
scale pragmatic trial.  At its completion, the trial might achieve preplanned levels 
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of statistical significance, but will anyone care?  At worst, the factors that bias the 
result to the null might entirely obliterate the ability of the study to detect a true 
treatment difference.  Certainly, if the pragmatic trial yields a false negative result 
or reports an effect size that appears tiny and unpersuasive by conventional 
standards, then even the paltry sums invested in it will have been wasted.  The 
widely-held belief that a pragmatic trial provides “real-world” evidence is 
seductively appealing, but no one has shown that such trials are more likely to 
yield the truth.  They are certainly more likely to yield results that do not matter. 
 
For these cogent reasons, pragmatic trials are unlikely to be utilized by the drug 
or device industry for the registration of novel interventions.  However, pragmatic 
trial designs might have a role in answering important questions about already-
approved medications, e.g., particularly in addressing uncertainties related to 
dose of an established drug or the comparative effectiveness of two treatments.  
The NHLBI is currently carrying out two large-scale pragmatic trials in patients 
with chronic heart failure.  The TRANSFORM trial9 will enroll 6000 recently-
hospitalized patients who will be randomized (open-label) to furosemide or 
torsemide, with total mortality as the primary endpoint.  The SPIRRIT trial10 
(carried out in partnership with the Swedish Heart Foundation and the Swedish 
Ministry of Health and Social Affairs) will enroll 3200 patients with chronic heart 
failure and an ejection fraction > 40%, who will be randomized (open-label) to 
receive spironolactone or no spironolactone and be followed for the occurrence 
of cardiovascular death or hospitalization for heart failure.  Ascertainment of 
study endpoints will be accomplished through national death index or healthcare 
registry.  Neither trial will rely on physical visits by participants to a clinical 
research site.  Conceivably, further technological advances (e.g. geofencing) 
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may allow trialists to reliably obtain information on patient outcomes without any 




If research in cardiovascular disease fails to identify critical causal abnormalities 
in highly select populations and if drug development continues to focus on the 
modulation of mechanisms that play only a small contributory role, then 
traditional large-scale clinical trials involving thousands of patients will be needed 
to demonstrate worthwhile treatment effects.  Because of the need to minimize 
operational factors that create statistical noise, these trials will continue to be 
extraordinarily expensive, and current trends in society and in medicine will 
continue to present important operational challenges.  If a traditionally-executed 
trial demonstrates a modest therapeutic effect but the price of the novel agent 
carries an innovative premium, the new drug may not be rapidly adopted, and the 
revenues that were used to justify the trial’s expense may not materialize in a 
timely manner.  Pragmatic trials are seductively less expensive, but may yield 
results that generate little enthusiasm or be difficult to interpret.  Therefore, 
unless the science underlying cardiovascular drug development changes 
dramatically, we may not need to worry about how large-scale clinical trials in 
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